Processing

Please wait...

Settings

Settings

1. WO2020009156 - BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE

Publication Number WO/2020/009156
Publication Date 09.01.2020
International Application No. PCT/JP2019/026483
International Filing Date 03.07.2019
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
C07D 401/12 (2006.01)
A61K 31/517 (2006.01)
A61P 35/00 (2006.01)
A61P 43/00 (2006.01)
C07D 401/14 (2006.01)
C07D 413/14 (2006.01)
CPC
A61K 31/517
A61P 35/00
A61P 43/00
C07D 401/12
C07D 401/14
C07D 413/14
Applicants
  • 第一三共株式会社 DAIICHI SANKYO COMPANY, LIMITED [JP/JP]; 東京都中央区日本橋本町三丁目5番1号 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo 1038426, JP
Inventors
  • 吉田 賢一 YOSHIDA Kenichi; JP
  • 竹内 孝輔 TAKEUCHI Kosuke; JP
  • 井上 英和 INOUE Hidekazu; JP
  • 影治 秀晃 KAGEJI Hideaki; JP
  • 百瀬 孝幸 MOMOSE Takayuki; JP
  • 吉田 佳右 YOSHIDA Keisuke; JP
  • 神保 猛 JIMBO Takeshi; JP
  • 江上 晶子 EGAMI Akiko; JP
Agents
  • 石橋 公樹 ISHIBASHI Koki; JP
  • 竹元 利泰 TAKEMOTO Toshiyasu; JP
Priority Data
2018-12782904.07.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE
(FR) DÉRIVÉ DE QUINAZOLINE DE TYPE ÉTHER DE BIARYLE
(JA) ビアリールエーテル型キナゾリン誘導体
Abstract
(EN)
The present invention provides a novel compound or a pharmaceutically acceptable salt thereof, having inhibitory action on an EGFR Tyr kinase having an exon 20 insertion mutation and/or on an HER2 Tyr kinase having an exon 20 insertion mutation. The invention is the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof. (In formula (I), R1, R2, R3, R4, R5, and R6, are each as defined in the specification.)
(FR)
La présente invention concerne un nouveau composé ou un sel pharmaceutiquement acceptable de celui-ci, présentant une action inhibitrice sur un EGFR Tyr Kinase ayant une mutation d'insertion d'exon 20 et/ou sur une kinase HER2 Tyr ayant une mutation d'insertion d'exon 20. L'invention concerne un composé représenté par la formule générale (I) ou un sel pharmaceutiquement acceptable de celui-ci. (Dans la formule (I), R1, R2, R3, R4, R5 et R6 sont chacun tels que définis dans la description.)
(JA)
本発明は、エクソン20挿入変異を有するEGFRチロシンキナーゼおよび/またはエクソン20挿入変異を有するHER2チロシンキナーゼ阻害作用を有する新規な化合物またはその製薬上許容される塩を提供するものである。 一般式(I)で表される化合物またはその製薬上許容される塩。(ここで、式(I)中のR、R、R、R、RおよびRは、それぞれ、明細書中の定義と同義である。)。
Latest bibliographic data on file with the International Bureau